TY - JOUR T1 - The cancer-testis gene, <em>MEIOB,</em> sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency JF - Cancer Biology and Medicine JO - Cancer Biol Med SP - 74 LP - 87 DO - 10.20892/j.issn.2095-3941.2020.0071 VL - 18 IS - 1 AU - Yayun Gu AU - Cheng Wang AU - Rongxuan Zhu AU - Jianshui Yang AU - Wenwen Yuan AU - Yanhui Zhu AU - Yan Zhou AU - Na Qin AU - Hongbing Shen AU - Hongxia Ma AU - Hongxia Wang AU - Xiaoan Liu AU - Zhibin Hu Y1 - 2021/02/01 UR - http://www.cancerbiomed.org/content/18/1/74.abstract N2 - Objective: The newly defined cancer-testis (CT) gene, MEIOB, was previously found to play key roles in DNA double-strand break (DSB) repair. In this study, we aimed to investigate the effects and mechanisms of MEIOB in the carcinogenesis of triple-negative breast cancers (TNBCs).Methods: The Cancer Genome Atlas database was used to quantify the expression of MEIOB. Cox regression analysis was used to evaluate the association between MEIOB expression and the prognosis of human TNBC. The effects of MEIOB on cell proliferation and migration in TNBCs were also assessed in vitro. Patient-derived xenograft (PDX) models were used to assess the sensitivity of breast cancers with active MEIOB to PARP1 inhibitors.Results: We confirmed MEIOB as a CT gene whose expression was restricted to the testes and breast tumors, especially TNBCs. Its activation was significantly associated with poor survival in breast cancer patients [overall, hazard ratio (HR) = 1.90 (1.16–2.06); TNBCs: HR = 7.05 (1.16–41.80)]. In addition, we found that MEIOB was oncogenic and significantly promoted the proliferation of TNBC cells. Further analysis showed that MEIOB participated in DSB repair in TNBCs. However, in contrast to its function in meiosis, it mediated homologous recombination deficiency (HRD) through the activation of polyADP-ribose polymerase (PARP)1 by interacting with YBX1. Furthermore, activated MEIOB was shown to confer sensitivity to PARP inhibitors, which was confirmed in PDX models.Conclusions: MEIOB played an oncogenic role in TNBC through its involvement in HRD. In addition, dysregulation of MEIOB sensitized TNBC cells to PARP inhibitors, so MEIOB may be a therapeutic target of PARP1 inhibitors in TNBC. ER -